Compare Gap Inc (GAP) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gap Inc trades at $22.66 (market cap $8.02B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Gap Inc is far larger — about 8.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gap Inc pays a 3.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GAP | MRVI | |
|---|---|---|
Market Cap | $8.02B | $972.90M |
Volume | 4,496,595 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $9.00 |
52-Week Low | $18.35 | $2.83 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $1.08B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $22.67, down 0.48% on the day, with a bullish technical signal supported by strong moving averages. The company shows improving fundamentals with revenue growth to $15.09B in 2025 and net income margin expanding to 8.14%. Recent strategic moves include music partnerships and board appointments, while analyst consensus targets $25.67 with 31% buy ratings.
The outlook remains positive with projected 2026 revenue of $15.3B and net income of $1.2B, though risks include Old Navy's sales decline and competitive pressures. Valuation appears attractive with P/E of 6.88 and P/S of 0.56, suggesting potential upside to consensus targets if execution continues.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
